ClinicalTrials.gg
RecruitingNCT04210284Updated Oct 30, 2026

Oral Nutritional Optimization in Total Joint Arthroplasty

An interventional study of Ensure in Osteoarthritis, sponsored by NYU Langone Health. Recruiting at 2 sites in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Non-randomized
Ages
55 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Osteoarthritis by NYU Langone Health — 1 open to participants now, 1 under way, none of them phase 3. Osteoarthritis · NYU Langone Health.

Planned enrollment
8th of 12
72 · median 76
Started
2021
the only one that year
No phase
7 of 12
1 open now
Registered
11th of 12
by date

Among the 12 studies in Osteoarthritis by NYU Langone Health, this one is the 8th largest by planned enrollment, is the only one that started in 2021, is one of 7 with no phase, and was the 11th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

1 of the 12 studies in Osteoarthritis by NYU Langone Health is open now, in 1 country.

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 55 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Osteoarthritis by NYU Langone Health, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effect on hematological markers of nutritional intervention on nutritionally deficient patients following total joint replacement surgery.

Read the detailed description

Numerous pre-operative modifiable variables have been extensively investigated for their effect on outcomes in TJA. These include metabolic diseases such as diabetes mellitus, obesity, and smoking status. However, nutritional status has not been as thoroughly investigated; to date, no prospective randomized control study has assessed the effect of oral nutritional supplementation for malnourished patients. This study will be a novel investigation into the role for routine serum screening for malnutrition as well as oral nutritional supplementation in TJA patients. This study could serve as a stepping stone towards creating a new pathway to highlight at-risk patients and pre-operatively optimizing their outcomes after TJA.

03

Conditions studied

  • Osteoarthritis

Browse trials for

04

Who can participate

Ages eligible
55 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient are current candidates for elective primary total hip and total knee arthroplasty
  2. Patients ≥55 years of age but ≤ 95
  3. Patients who meet at least one of the following three laboratory criteria for malnutrition:

TSerum Albumin: ≤3.5 mg/dl Pre-Albumin: \<15 mg/dl Transferrin: \<200 mg/dl

Exclusion criteria

Exclusion Criteria:

  1. Previous history of septic arthritis
  2. Allergy to oral supplementation
  3. Inability to consume oral supplementation
  4. Protein malabsorption syndromes
  5. Eating disorders
  6. End stage renal and hepatic disease
  7. Revision surgery, non-elective surgery, hemiarthroplasty, and unicompartmental knee arthroplasty
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
72 participants (estimated)

Study arms

  • Experimental
    Nutritional supplementation

    Given Ensure Max Protein Nutrition shake 2 weeks before surgery and continued 2 weeks after surgery.

    Dietary Supplement: Ensure

  • No intervention
    No Nutritional supplementation

    Treatment as usual

Interventions

  • Dietary supplementNutritional Supplement DrinkStudies of Nutritional Supplement DrinkNutritional Supplement Drink pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Ensure Max Protein Shake is an over the counter available drinkable nutritional supplement. Per serving, it contains: * 160 Calories, 20 from fat * 2g Total fat * 0.5g Saturated fat * 20mg Cholesterol * 135mg Sodium * 170mg Potassium * 19g Total carbohydrate * \<1g Fiber * 4g Sugar * 16g Protein Participants will receive Ensure High Protein for 2 weeks pre- and 4 weeks post-operatively. These patients will be instructed to consume 1 serving (16fl oz) of Ensure High Protein daily. They will be provided with this product at a pre-operative clinical visit or have it mailed to their home. Hematologic nutritional values will be measured as specified previously. Descriptive statistics will be used to report baseline characteristics and primary study objectives. Hematologic outcomes will be compared between the control ("NO ENSURE") and oral supplementation ("ENSURE") arms for the aforementioned baseline and perioperative variables

06

What researchers measure

Primary outcomes

  1. Changes in the patients' albumin, pre-albumin, and/or transferrin levels

    Biological specimen collection and laboratory evaluations- all included patients' hematologic markers of malnutrition (albumin, pre-albumin, and transferrin) will be recorded at 2 weeks prior to surgery, the day of surgery, and 6 weeks. These blood tests can all be performed from one sample of blood at each visit. The results will then be accessed via the EMR

    Time frame: Visit 2 (2 wks pre) Visit 3 (surgery day) Visit 5 (4 weeks post)

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.

Access criteria: The investigator who proposed to use the data. Upon reasonable request Requests should be directed to Daniel.waren@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Dec 2026, 65 months after the start.

Of 578 non-industry interventional studies with no phase under Osteoarthritis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 51. This study's planned 65 months is above that.

Counting every sponsor, half of 713 studies reached it within 28 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2019
First posted
Dec 24, 2019
StartActual
Jul 6, 2021
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2027
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04210284
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Dec 24, 2019
Start date
Jul 6, 2021
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 30, 2026

Study contacts

Daniel Waren
Contact
Daniel.waren@nyulangone.org
212-598-6245
Ran Schwarzkopf
principal investigator · NYU Langone

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nutritional Supplement Drink

Start the discussion